Package Leaflet: Information for the User
PritorPlus 80 mg/12.5 mg tablets
telmisartan/hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
PritorPlus is a combination of two active substances, telmisartan and hydrochlorothiazide, in one tablet. Both active substances help to control high blood pressure.
High blood pressure, if left untreated, can damage blood vessels in various organs, which can sometimes lead to heart attack, heart failure, kidney failure, stroke, or blindness.
Usually, there are no symptoms of high blood pressure before damage occurs. Therefore, it is important to regularly check your blood pressure to ensure it is within the normal range.
PritorPlus is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled with telmisartan alone.
Do not take PritorPlus
If any of the above applies to you, tell your doctor or pharmacist before taking PritorPlus.
Warnings and precautions
Tell your doctor before taking PritorPlus if you have or have had any of the following conditions or diseases:
Tell your doctor before taking PritorPlus:
Your doctor may need to check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals. See also the information under the heading "Do not take PritorPlus".
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor. PritorPlus is not recommended during the first few months of pregnancy (first trimester) and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby (see section Pregnancy).
Treatment with hydrochlorothiazide may cause an electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, somnolence, restlessness, muscle pain or cramps, nausea, vomiting, muscle fatigue, and an abnormally fast heart rate (more than 100 beats per minute). If you experience any of these symptoms, inform your doctor.
You should also inform your doctor if you experience increased sensitivity of your skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) that appear more quickly than usual.
If you are going to have surgery or anesthesia, inform your doctor that you are taking PritorPlus.
PritorPlus may be less effective in reducing blood pressure in black patients.
Children and adolescents
PritorPlus is not recommended for use in children and adolescents up to 18 years of age.
Other medicines and PritorPlus
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Your doctor may need to change the dose of these other medicines or take other precautions. In some cases, it may be necessary to stop taking one of these medicines, especially if you are taking PritorPlus with any of the following medicines:
PritorPlus may increase the effect of other medicines to lower blood pressure or medicines that may potentially lower blood pressure (e.g., baclofen, amifostine). Additionally, the reduction in blood pressure may be increased by alcohol, barbiturates, narcotics, or antidepressants. You may notice this effect as dizziness when standing up. You should inform your doctor about the need to adjust the dose of your other medicines while taking PritorPlus.
The effect of PritorPlus may be reduced when taking NSAIDs (non-steroidal anti-inflammatory drugs, e.g., aspirin or ibuprofen).
Taking PritorPlus with food and drink
You can take PritorPlus with or without food.
Avoid drinking alcohol until you have talked to your doctor. Alcohol may further lower your blood pressure and/or increase the risk of feeling dizzy or weak.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking PritorPlus before you become pregnant or as soon as you find out you are pregnant, and will recommend that you take another medicine to lower your blood pressure instead. PritorPlus is not recommended during pregnancy and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby when taken after this time.
Breastfeeding
Inform your doctor if you are about to start or are already breastfeeding, as it is not recommended to take PritorPlus during this time. Your doctor may decide to give you a different treatment that is more suitable if you want to breastfeed.
Driving and using machines
Some patients feel dizzy or tired when taking PritorPlus. If you feel dizzy or tired, do not drive or use machines.
PritorPlus contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
PritorPlus contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
PritorPlus contains sorbitol
This medicine contains 338 mg of sorbitol in each tablet. Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars, or you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which you cannot break down fructose, consult your doctor before taking this medicine.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is one tablet per day. Try to take one tablet each day at the same time. You can take PritorPlus with or without food. The tablets should be swallowed with a little water or other non-alcoholic drink. It is important that you take PritorPlus every day until your doctor tells you to stop.
If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once daily.
If you take more PritorPlus than you should
If you accidentally take too many tablets, you may experience symptoms such as low blood pressure and a fast heart rate. Slow heart rate, dizziness, vomiting, and reduced kidney function, including kidney failure, have also been reported. Due to the hydrochlorothiazide component, you may also experience very low blood pressure and low potassium levels in the blood, which can lead to nausea, somnolence, and muscle cramps and/or irregular heartbeats associated with the concomitant use of medicines like digitalis or certain antiarrhythmic treatments. Contact your doctor or pharmacist or the nearest hospital emergency department immediately.
If you forget to take PritorPlus
If you forget to take your medicine, do not worry. Take the dose as soon as you remember and then continue as before. If you do not take your tablet one day, take your normal dose the next day. Do not takea double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Some adverse effects can be serious and require immediate medical attention:
If you experience any of the following symptoms, you should visit your doctor immediately:
Sepsis* (frequently called "blood infection"), is a serious infection that involves an inflammatory reaction of the entire body, rapid swelling of the skin and mucous membranes (angioedema), blistering and peeling of the outer layer of the skin (toxic epidermal necrolysis); these adverse effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and visit their doctor immediately. If these adverse effects are not treated, they can be fatal. An increase in the incidence of sepsis has been observed with telmisartan alone; however, it cannot be ruled out for PritorPlus.
Possible Adverse Effects of PritorPlus:
Frequent Adverse Effects (may affect up to 1 in 10 people)
Dizziness.
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Decrease in potassium levels in the blood, anxiety, fainting (syncope), tingling sensation, numbness (paresthesia), dizziness (vertigo), rapid heartbeat (tachycardia), heart rhythm disturbances, low blood pressure, sudden decrease in blood pressure when standing up, shortness of breath (dyspnea), diarrhea, dry mouth, flatulence, back pain, muscle spasms, muscle pain, erectile dysfunction (inability to have or maintain an erection), chest pain, and increased uric acid levels in the blood.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Lung inflammation (bronchitis), activation or worsening of systemic lupus erythematosus (a disease in which the body's immune system attacks the body itself, causing joint pain, skin rashes, and fever), sore throat, sinus inflammation, feeling of sadness (depression), difficulty falling asleep (insomnia), vision disturbances, breathing difficulties, abdominal pain, constipation, abdominal distension (dyspepsia), general malaise (vomiting), stomach inflammation (gastritis), liver function disorders (Japanese patients show a greater tendency to experience this adverse effect), skin redness (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia), and pain in the limbs, muscle cramps, pseudo-influenza syndrome, pain, low sodium levels, increased creatinine, liver enzymes, or creatine phosphokinase levels in the blood.
Adverse reactions reported for one of the individual components may be potential adverse reactions of PritorPlus, even if they have not been observed in clinical trials with this product.
Telmisartan
The following additional adverse effects have been described in patients taking telmisartan alone:
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Upper respiratory tract infection (e.g., sore throat, sinusitis, common cold), urinary tract infections, red blood cell deficiency (anemia), high potassium levels, slow heart rate (bradycardia), cough, kidney function disorders including acute renal failure, weakness.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Low platelet count (thrombocytopenia), increased white blood cell count (eosinophilia), severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions, drug rash), low blood sugar levels (in diabetic patients), drowsiness, stomach discomfort, eczema (a skin disorder), osteoarthritis, tendon inflammation, decreased hemoglobin (a blood protein).
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Progressive lung tissue fibrosis (interstitial lung disease)**
** Cases of progressive lung tissue fibrosis have been reported during telmisartan treatment. However, it is unknown whether telmisartan was the cause.
Hydrochlorothiazide
The following additional adverse effects have been described in patients taking hydrochlorothiazide alone:
Frequent Adverse Effects (may affect up to 1 in 10 people)
Nausea, low magnesium levels in the blood.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Decreased platelet count in the blood, which increases the risk of bleeding and bruising (small purple-red marks on the skin or other tissues caused by bleeding), high calcium levels in the blood, headache.
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Increased pH (acid-base imbalance) due to low chloride levels in the blood, acute respiratory distress (symptoms include severe respiratory distress, fever, weakness, and confusion).
Unknown Frequency (cannot be estimated from available data)
Salivary gland inflammation, skin and lip cancer (non-melanoma skin cancer), decreased blood cell count, including low red and white blood cell count, severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions), decreased or lost appetite, restlessness, dizziness, blurred or yellowish vision, decreased vision, and eye pain (possible signs of fluid accumulation in the vascular layer of the eye [choroidal effusion] or acute angle-closure glaucoma), blood vessel inflammation (necrotizing vasculitis), pancreatitis, stomach discomfort, yellowing of the skin or eyes (jaundice), pseudo-lupus syndrome (a condition that mimics systemic lupus erythematosus), skin disorders such as blood vessel inflammation of the skin, increased sensitivity to sunlight, skin rash, redness of the skin, blistering of the lips, eyes, or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or dysfunction, glucose in the urine (glucosuria), fever, electrolyte imbalance, high cholesterol levels in the blood, decreased blood volume, increased glucose levels in the blood, difficulty controlling blood sugar levels in patients with diabetes mellitus, or fat in the blood.
Reporting Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require any special storage temperature. Store in the original packaging to protect it from moisture. Remove your PritorPlus tablet from the blister pack just before taking it.
Occasionally, the outer layer of the blister pack separates from the inner layer between the blister pack cavities. If this is detected, no action is required on your part.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
PritorPlus Composition
The active ingredients are telmisartan and hydrochlorothiazide.
Each tablet contains 80 mg of telmisartan and 12.5 mg of hydrochlorothiazide.
The other ingredients are lactose monohydrate, magnesium stearate, corn starch, meglumine, microcrystalline cellulose, povidone K25, red iron oxide (E172), sodium hydroxide, sodium starch glycolate (type A), and sorbitol (E420).
Product Appearance and Package Contents
PritorPlus 80 mg/12.5 mg tablets are oblong, two-layer tablets, red and white, engraved with the code 'H8'.
PritorPlus is available in blister packs containing 14, 28, 30, 56, 90, or 98 tablets, or in single-dose blister packs containing 28 x 1 tablets.
Not all pack sizes may be marketed in your country.
Marketing Authorization Holder
Bayer AG
51368 Leverkusen
Germany
Manufacturer
Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder.
België / Belgique / Belgien Bayer SA-NV Tél/Tel: +32-(0)2-535 63 11 | Lietuva UAB Bayer Tel. +37 05 23 36 868 |
Luxembourg / Luxemburg Bayer SA-NV Tél/Tel: +32-(0)2-535 63 11 | |
Ceská republika Bayer s.r.o. Tel: +420 266-101-111 | Magyarország Bayer Hungária Kft. Tel.:+36-14 87-41 00 |
Danmark Bayer A/S Tlf: +45-45 23 50 00 | Malta Alfred Gera and Sons Ltd. Tel: +356-21 44 62 05 |
Deutschland Bayer Vital GmbH Tel: +49-(0)214-30 513 48 | Nederland Bayer B.V. Tel: +31-(0)297-28 06 66 |
Eesti Bayer OÜ Tel: +372 655 85 65 | Norge Bayer AS Tlf. +47 23 13 05 00 |
Ελλáδα Bayer Ελλáς ΑΒΕΕ Τηλ: +30 210 618 75 00 | Österreich Bayer Austria Ges. m. b. H. Tel: +43-(0)1-711 46-0 |
España Bayer Hispania S.L. Tel: +34-93-495 65 00 | Polska Bayer Sp. z o.o. Tel.: +48-22-572 35 00 |
France Bayer HealthCare Tél (Nº vert): +33-(0)800 87 54 54 | Portugal Bayer Portugal Lda Tel: +351-21-416 42 00 |
Hrvatska Bayer d.o.o. Tel: + 385-(0)1-6599 900 | România SC Bayer SRL Tel.: +40 21 528 59 00 |
Ireland Bayer Limited Tel: +353-1-216-3300 | Slovenija Bayer d. o. o. Tel.: +386-1-58 14 400 |
Ísland Icepharma hf. Sími: +354 540 8000 | Slovenská republika Bayer, spol. s r.o. Tel: +421 2 59 21 31 11 |
Italia Bayer S.p.A. Tel: +39-02-397 81 | Suomi/Finland Bayer Oy Puh/Tel.: +358-20 785 21 |
Κúπρος NOVAGEM Limited Τηλ: + 357 22 48 38 58 | Sverige Bayer AB Tel: +46-(0)8-580 223 00 |
Latvija SIA Bayer Tel: +371 67 84 55 63 | United Kingdom (Northern Ireland) Bayer AG Tel: +44 (0) 118 206 30 00 |
Date of Last Revision of this Leaflet:{MM/AAAA}.
Other Sources of Information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.